CoDiagnostics Secures Japanese Patent, Enhancing Molecular Diagnostics and Point-of-Care Testing Solutions

CoDiagnostics Strengthens Intellectual Property Portfolio with Recent Patent in Japan

CoDiagnostics, Inc. (Nasdaq: CODX), a leader in molecular diagnostics, achieves a significant milestone with the granting of Japanese Patent No. 7797537 by the Japan Patent Office (JPO) for its innovative platform titled "Systems, Methods, and Apparatus for Automated Self-Contained Biological Analysis." This patent, registered on December 26, 2025, consists of 34 claims that enhance Co-Diagnostics’ intellectual property, particularly in relation to its Co-Dx PCR Pro® instrument and point-of-care testing solutions. The patent underscores the company’s commitment to advancing infectious disease diagnostics, reflecting the unique nature of its technology as confirmed by the rigorous review process undertaken by the JPO.

Dwight Egan, CEO of Co-Diagnostics, emphasizes the importance of this patent in solidifying the company’s position within the global molecular diagnostics landscape. The recently acquired patent represents a strategic move to enhance the company’s competitive edge in several key international markets, including Japan. Following a similar patent granted by the Australian Patent Office in 2025, this development not only broadens CoDiagnostics' intellectual property base but also supports its aggressive stance toward international expansion and commercialization of its testing solutions. The patent specifically relates to the company’s focus on decentralized testing, which aims to provide high-standard PCR accuracy in a compact, user-friendly device tailored for point-of-care applications.

The Co-Dx PCR platform incorporates Co-Primers® technology, integral in delivering rapid molecular diagnostics across a variety of applications. The detailed claims within the new patent articulate the foundational technologies that power the Co-Dx system, including the instrument itself and proprietary test cups. As Co-Diagnostics advances this initiative, the company stands poised to explore commercial opportunities and foster collaborations that will enhance the accessibility of affordable and high-performance PCR testing solutions, particularly in growing markets. It is noteworthy that, while the Co-Dx PCR platform shows great promise, it is still pending regulatory review and is not yet commercially available.

In addition to strengthening its patent portfolio, CoDiagnostics' efforts signify a vital step toward expanding access to critical diagnostics that can streamline testing processes in infectious disease management. As the healthcare sector increasingly turns toward innovative technologies for tackling public health challenges, Co-Diagnostics’ advancements could play a pivotal role in enhancing the efficacy and speed of diagnostic testing worldwide. With the continuing global focus on decentralized healthcare solutions, the company is positioned to lead in the rapidly evolving landscape of molecular diagnostics.